- Home
- NBIX
as of 12-17-2025 3:38pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 15.2B | IPO Year: | 1996 |
| Target Price: | $176.19 | AVG Volume (30 days): | 952.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.19 | EPS Growth: | 12.44 |
| 52 Week Low/High: | $84.23 - $160.18 | Next Earning Date: | 02-05-2026 |
| Revenue: | $2,682,700,000 | Revenue Growth: | 19.61% |
| Revenue Growth (this year): | 23.76% | Revenue Growth (next year): | 18.01% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
Director
Avg Cost/Share
$155.09
Shares
1,190
Total Value
$184,558.41
Owned After
6,239
SEC Form 4
Director
Avg Cost/Share
$152.23
Shares
5,000
Total Value
$761,143.50
Owned After
6,239
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$159.65
Shares
4,376
Total Value
$698,615.27
Owned After
43,405
SEC Form 4
Director
Avg Cost/Share
$152.61
Shares
15,000
Total Value
$2,289,082.50
Owned After
120,482
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$151.74
Shares
5,970
Total Value
$905,880.64
Owned After
44,893
SEC Form 4
Director
Avg Cost/Share
$143.37
Shares
15,000
Total Value
$2,150,512.50
Owned After
7,068
SEC Form 4
Director
Avg Cost/Share
$151.82
Shares
18,000
Total Value
$2,732,689.80
Owned After
40,360
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Norwalk Leslie V | NBIX | Director | Dec 16, 2025 | Sell | $155.09 | 1,190 | $184,558.41 | 6,239 | |
| Norwalk Leslie V | NBIX | Director | Dec 15, 2025 | Sell | $152.23 | 5,000 | $761,143.50 | 6,239 | |
| Lippoldt Darin | NBIX | Chief Legal Officer | Dec 8, 2025 | Sell | $159.65 | 4,376 | $698,615.27 | 43,405 | |
| LYONS GARY A | NBIX | Director | Dec 3, 2025 | Sell | $152.61 | 15,000 | $2,289,082.50 | 120,482 | |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Nov 28, 2025 | Sell | $151.74 | 5,970 | $905,880.64 | 44,893 | |
| MORROW GEORGE J | NBIX | Director | Nov 25, 2025 | Sell | $143.37 | 15,000 | $2,150,512.50 | 7,068 | |
| RASTETTER WILLIAM H | NBIX | Director | Nov 5, 2025 | Sell | $151.82 | 18,000 | $2,732,689.80 | 40,360 | |
| Gano Kyle | NBIX | Chief Executive Officer | Nov 4, 2025 | Sell | $141.97 | 300 | $42,591.00 | 140,407 |
Compare NBIX vs Leading Stocks
See how NBIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.